AstraZeneca Pharma Stock Screener | Share Price & Fundamental Analysis
ASTRAZEN
Pharmaceuticals
Screen AstraZeneca Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹8400.00
▼
-38.00 (-0.45%)
Share Price BSE
₹8395.15
▼
-36.55 (-0.43%)
Market Cap
₹21,943.75 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
28.19
EPS (TTM)
₹46.30
Dividend Yield
0.36%
Debt to Equity
0.03
52W High
₹10509.50
52W Low
₹6698.65
Operating Margin
14.00%
Profit Margin
9.72%
Revenue (TTM)
₹2,048.00
EBITDA
₹316.00
Net Income
₹199.00
Total Assets
₹1,518.00
Total Equity
₹770.00
AstraZeneca Pharma Share Price History - Stock Screener Chart
Screen ASTRAZEN historical share price movements with interactive charts. Analyze price trends and patterns.
AstraZeneca Pharma Company Profile - Fundamental Screener
Screen AstraZeneca Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ASTRAZEN shares.
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Shilpa Divekar Nirula
ISIN
INE203A01020
Website
https://www.astrazeneca.in
AstraZeneca Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ASTRAZEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,518 | 1,078 | 985 | 857 | 775 | 706 | 562 | 461 | 416 | 403 |
| Current Assets | 1,342 | 933 | 836 | 706 | 619 | 542 | 405 | 321 | 252 | 267 |
| Fixed Assets | 64 | 67 | 69 | 75 | 81 | 72 | 75 | 76 | 87 | 97 |
| Liabilities | ||||||||||
| Total Liabilities | 1,518 | 1,078 | 985 | 857 | 775 | 706 | 562 | 461 | 416 | 403 |
| Current Liabilities | 45 | 9 | 12 | 13 | 15 | 15 | 2 | 7 | 2 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 770 | 712 | 589 | 511 | 456 | 364 | 301 | 247 | 223 | 156 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 765 | 707 | 584 | 506 | 451 | 359 | 296 | 242 | 218 | 151 |
Screen ASTRAZEN income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,048 | 1,757 | 1,330 | 1,029 | 820 | 826 | 845 | 745 | 583 | 558 | 571 | 523 |
| Expenses | 1,732 | 1,462 | 1,111 | 838 | 719 | 678 | 711 | 657 | 525 | 507 | 547 | 529 |
| EBITDA | 316 | 295 | 219 | 191 | 101 | 148 | 134 | 88 | 59 | 51 | 23 | -6 |
| Operating Profit % | 14.00% | 15.00% | 14.00% | 16.00% | 11.00% | 17.00% | 15.00% | 10.00% | 8.00% | 7.00% | 3.00% | -2.00% |
| Depreciation | 46 | 40 | 15 | 16 | 17 | 20 | 19 | 15 | 15 | 16 | 17 | 15 |
| Interest | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 268 | 156 | 220 | 134 | 83 | 127 | 114 | 73 | 44 | 36 | 6 | -21 |
| Tax | 76 | 41 | 58 | 35 | 21 | 34 | 42 | 18 | 18 | 15 | 1 | 0 |
| Net Profit | 199 | 116 | 162 | 99 | 62 | 93 | 72 | 54 | 26 | 20 | 5 | -21 |
| EPS | 79.70 | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | -8.34 |
AstraZeneca Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ASTRAZEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 65 | 28 | 58 | 101 | 105 | 87 | 55 | 9 | 38 | 57 |
| Investing Activities | 31 | 22 | 18 | 5 | 173 | -171 | 4 | -9 | 0 | -4 |
| Financing Activities | -66 | -44 | -25 | -10 | -9 | -6 | 0 | 0 | 0 | -1 |
| Net Cash Flow | 31 | 5 | 52 | 96 | 269 | -90 | 59 | -1 | 38 | 53 |
Screen ASTRAZEN shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 2.74% | 3.03% | 2.89% | 2.93% | 2.90% | 2.79% | 2.74% | 0.00% |
| DII Holding | 5.26% | 4.56% | 4.65% | 5.22% | 5.10% | 5.01% | 3.78% | 2.75% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 14.39% | 15.18% | 15.16% | 14.62% | 14.77% | 15.00% | 16.33% | 17.09% |
| Other Holding | 2.61% | 2.23% | 2.31% | 2.24% | 2.23% | 2.20% | 2.15% | 5.15% |
| Shareholder Count | 32,914 | 34,378 | 32,466 | 27,322 | 27,615 | 27,169 | 29,418 | 29,032 |
AstraZeneca Pharma Dividend Screener - Share Yield Analysis
Screen ASTRAZEN dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹32.00 | 0.35% |
| 2024-March | ₹24.00 | 0.28% |
| 2023-March | ₹16.00 | 0.30% |
| 2022-March | ₹10.00 | 0.31% |
| 2021-March | ₹2.00 | 0.08% |
| 2020-March | ₹1.00 | 0.03% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
AstraZeneca Pharma Index Membership - Market Screener Classification
Screen ASTRAZEN by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
AstraZeneca Pharma Market Events Screener - Corporate Actions
Screen ASTRAZEN market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -1.29% |
| 2025-08-14 | 2025-08-14 | Annual General Meeting | NA | -4.71% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -6.00% |
| 2025-07-18 | 2025-07-18 | Dividend | ₹ 32.00 /share | 18.54% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.03% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 8.88% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 3.57% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | 7.26% |
| 2024-07-05 | 2024-07-05 | Dividend | ₹ 24.00 /share | 18.44% |
| 2023-07-14 | 2023-07-14 | Dividend | ₹ 16.00 /share | 15.81% |
| 2022-08-08 | 2022-08-08 | Annual General Meeting | NA | 3.23% |
| 2022-07-07 | 2022-07-08 | Dividend | ₹ 8.00 /share | 10.01% |
| 2021-08-18 | 2021-08-20 | Dividend | ₹ 2.00 /share | -8.95% |
AstraZeneca Pharma Competitors Screener - Peer Comparison
Screen ASTRAZEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
AstraZeneca Pharma Company Announcements - News Screener
Screen ASTRAZEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-17 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2025-12-15 | Closure of Trading Window | View |
| 2025-12-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-08 | Determination Of Materiality - Details Of Key Managerial Personnel | View |
| 2025-11-27 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-18 | Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-17 | Intimation About Second Brand Partnership Between Astrazeneca Pharma India Limited ("Company") And Sun Pharmaceuticals Industries Limited For Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5 G | View |
| 2025-11-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-07 | Outcome Of The Board Meeting Held On Friday November 7 2025 | View |
| 2025-10-27 | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday November 7 2025 | View |
| 2025-10-15 | Launch Of Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5G (Lokelma) | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-03 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2025-09-19 | Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-09-12 | Closure of Trading Window | View |
| 2025-09-12 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-09-12 | Disclosure under Regulation 30A of LODR | View |